Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 190

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML

Open access
Stahl, Maximilian, Menghrajani, Kamal, Derkach, Andriy, Chan, Alexander, Xiao, Wenbin, Glass, Jacob, King, Amber C., Daniyan, Anthony F., Famulare, Christopher, Cuello, Bernadette M., Horvat, Troy Z., Abdel-Wahab, Omar, Levine, Ross L., Viny, Aaron D., Stein, Eytan M., Cai, Sheng F., Roshal, Mikhail, Tallman, Martin S., Goldberg, Aaron D. · 2021 · Blood Advances

Abstract

Azacitidine + venetoclax, decitabine + venetoclax, and low-dose cytarabine + venetoclax are now standard treatments for newly diagnosed older or unfit patients with acute myeloid leukemia (AML). Although these combinations are also commonly used in relapsed or refractory AML (RR-AML), clinical and molecular predictors of response and survival in RR-AML are incompletely understood. We retrospectively analyzed clinical and molecular characteristics and outcomes for 86 patients with RR-AML who were treated with venetoclax combinations. The complete remission (CR) or CR with incomplete hematologic recovery (CRi) rate was 24%, and the overall response rate was 31% with the inclusion of a morphologic leukemia-free state. Azacitidine + venetoclax resulted in higher response rates compared with low-dose cytarabine + venetoclax (49% vs 15%; P = .008). Median overall survival (OS) was 6.1 months, but it was significantly longer with azacitidine + venetoclax compared with low-dose cytarabine + venetoclax (25 vs 3.9 months; P = .003). This survival advantage of azacitidine + venetoclax over low-dose cytarabine + venetoclax persisted when patients were censored for subsequent allogeneic stem cell transplantation (8.1 vs 3.9 months; P = .035). Mutations in NPM1 were associated with higher response rates, whereas adverse cytogenetics and mutations in TP53, KRAS/NRAS, and SF3B1 were associated with worse OS. Relapse was driven by diverse mechanisms, including acquisition of novel mutations and an increase in cytogenetic complexity. Venetoclax combination therapy is effective in many patients with RR-AML, and pretreatment molecular characteristics may predict outcomes. Trials that evaluate novel agents in combination with venetoclax therapy in patients with RR-AML that have adverse risk genomic features are warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/bloodadvances.2020003734

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 190

Metadata

Authors
Stahl, M., Menghrajani, K., Derkach, A., Chan, A., Xiao, W., Glass, J., King, A. C., Daniyan, A. F., Famulare, C., Cuello, B. M., Horvat, T. Z., Abdel-Wahab, O., Levine, R. L., Viny, A. D., Stein, E. M., Cai, S. F., Roshal, M., Tallman, M. S., & Goldberg, A. D.
Venue
Blood Advances
Published
2021-03-09
Volume
5
Issue
5
Pages
1552-1564
ISSN
  • 2473-9529 (ISSN-L)
  • 2473-9537
OpenAlex
W3135596931
Cited by
190
References
3
FWCI
19.29
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. https://app.cochat.ai/papers/10.1182/bloodadvances.2020003734
The paper
Stahl, M., Menghrajani, K., Derkach, A., Chan, A., Xiao, W., Glass, J., King, A. C., Daniyan, A. F., Famulare, C., Cuello, B. M., Horvat, T. Z., Abdel-Wahab, O., Levine, R. L., Viny, A. D., Stein, E. M., Cai, S. F., Roshal, M., Tallman, M. S., & Goldberg, A. D. (2021). Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Blood Advances. https://doi.org/10.1182/bloodadvances.2020003734

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.